MNMD - Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow | Benzinga
Welcome to a new episode of the Benzinga Psychedelics Podcast where we’re joined by Robert Barrow, CEO of Mind Medicine (MindMed) (NASDAQ:MNMD), which has taken the development of LSD-based therapy to new heights. The biopharma company recently obtained a "breakthrough therapy" designation for the treatment of generalized anxiety from the U.S. Food and Drug Administration (FDA.)
LSD, illegal in the U.S., is classified by the Drug Enforcement Agency (DEA) as a Schedule I drug -meaning it has a high potential for abuse and no currently accepted medical treatments.
However, there is growing interest in LSD's potential therapeutic uses for conditions like alcoholism, depression and anxiety. Studies like MIndMed's are moving closer to proving its benefits.
In our podcast, we delve into LSD's universe and particularly how MindMed is advancing the clinical development of its LSD-like drug, MM-120, for the treatment of Generalized Anxiety Disorder. We look at the ...